CCA
IRWD icon

Cruiser Capital Advisors’s Ironwood Pharmaceuticals IRWD Stock Holding History

Cruiser Capital Advisors’s Portfolio IRWD Stock Details IRWD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-15,000
Closed -$168K – 58
2021
Q1 		$168K Buy
+15,000
New +$158K 0.15% 40

Other funds holding IRWD

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BCM
Brown Capital Management Baltimore, Maryland $704M AUM 6.25% 1-Year Est. Return
SCM
Sarissa Capital Management Greenwich, Connecticut $158M AUM 103.7% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return
PI
Putnam Investments Boston, Massachusetts $75.7B AUM 34.45% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return

Cruiser Capital Advisors's IRWD Position: Q2 2021 in Review

Cruiser Capital Advisors sold out of Ironwood Pharmaceuticals (IRWD) in Q2 2021, closing a stake of 15,000 shares — an estimated $168K sold.

Cruiser Capital Advisors first reported a position in IRWD in Q1 2021 and held it in 1 quarter. The position peaked at $168K in Q1 2021. 208 funds tracked by Wall St. Rank hold IRWD as of Q2 2021.

  • Cruiser Capital Advisors reported no remaining Ironwood Pharmaceuticals position as of Q2 2021 after selling out during the quarter.
  • Cruiser Capital Advisors sold 15,000 Ironwood Pharmaceuticals shares in Q2 2021, an estimated $168K.
  • Cruiser Capital Advisors first reported a position in Ironwood Pharmaceuticals in Q1 2021 and held it in 1 quarter.
  • Cruiser Capital Advisors's Ironwood Pharmaceuticals position peaked at $168K in Q1 2021.
  • 208 funds tracked by Wall St. Rank held Ironwood Pharmaceuticals as of Q2 2021.

Based on Cruiser Capital Advisors's 13F filing for Q2 2021, filed 16 Aug 2021.